Insider · CIK 0001632385

Farrell Geraldine T

Reports to the SEC for 1 company · BLACKROCK, L2

sec.gov

Transactions

Companies

Filings

CIK

0001632385

Forms 4 and 5

Insider transactions

34 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2017-07-31	Nexvet Biopharma plcD Disposition to Issuer	VP Operations, General Counsel	DDisposition to Issuer	−33.2K sh	$6.72	−$223K	0
2017-07-31	Nexvet Biopharma plcRestricted Share UnitsD Disposition to Issuer	VP Operations, General Counsel	DDisposition to Issuer	−30K sh	$6.59	−$198K	0
2017-07-31	Nexvet Biopharma plcD Disposition to Issuer	VP Operations, General Counsel	DDisposition to Issuer	−19K sh	$6.72	−$128K	0
2017-07-31	Nexvet Biopharma plcOption to Purchase SharesD Disposition to Issuer	VP Operations, General Counsel	DDisposition to Issuer	−20K sh	—	—	0
2017-07-01	Nexvet Biopharma plcRestricted Share UnitsM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	−10K sh	—	—	30,000
2017-07-01	Nexvet Biopharma plcRestricted Share UnitsM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	−2,340 sh	—	—	4,678
2017-07-01	Nexvet Biopharma plcOption to Purchase SharesM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	−2,866 sh	—	—	0
2017-07-01	Nexvet Biopharma plcOption to Purchase SharesM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	−6,194 sh	—	—	0
2017-07-01	Nexvet Biopharma plcRestricted Share UnitsD Disposition to Issuer	VP Operations, General Counsel	DDisposition to Issuer	−4,678 sh	$6.59	−$30.9K	0
2017-07-01	Nexvet Biopharma plcM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	+10K sh	$0.13	+$1,250	16,640
2017-07-01	Nexvet Biopharma plcM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	+2,340 sh	$0.13	+$292.5	18,980
2017-07-01	Nexvet Biopharma plcM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	+2,866 sh	$0.13	+$358.25	26,986
2017-07-01	Nexvet Biopharma plcM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	+6,194 sh	$0.13	+$774.25	33,180
2016-09-05	Nexvet Biopharma plcRestricted Share UnitsM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	+40K sh	—	—	40,000
2016-07-01	Nexvet Biopharma plcM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	+2,867 sh	$0.13	+$358.375	24,120
2016-07-01	Nexvet Biopharma plcM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	+2,340 sh	$0.13	+$292.5	6,640
2016-07-01	Nexvet Biopharma plcOptions to Purchase SharesM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	−2,867 sh	—	—	2,866
2016-07-01	Nexvet Biopharma plcRestricted Share UnitsM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	−2,340 sh	—	—	7,018
2016-03-03	Nexvet Biopharma plcS Sale	VP Operations, General Counsel	SSale	−132 sh	$3.27	−$431.653	0
2015-11-23	Nexvet Biopharma plcM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	+4,300 sh	$0.13	+$537.5	21,253
2015-11-23	Nexvet Biopharma plcOptions to purchase sharesM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	−4,300 sh	—	—	5,733
2015-11-05	Nexvet Biopharma plcM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	+6,195 sh	$0.13	+$774.375	16,953
2015-11-05	Nexvet Biopharma plcOptions to purchase sharesM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	−6,195 sh	—	—	6,194
2015-09-03	Nexvet Biopharma plcRestricted Share UnitsA Award	VP Operations, General Counsel	AAward	+9,358 sh	—	—	9,358
2015-07-01	Nexvet Biopharma plcM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	+2,867 sh	$0.13	+$358.375	10,758
2015-07-01	Nexvet Biopharma plcOptions to purchase sharesM Exercise/Conversion	VP Operations, General Counsel	MExercise/Conversion	−2,867 sh	—	—	10,033
2015-06-08	Nexvet Biopharma plcA Award	VP Operations, General Counsel	AAward	+4,300 sh	$0.13	+$537.5	4,300
2015-05-18	Nexvet Biopharma plcOptions to Purchase SharesA Award	VP Operations, General Counsel	AAward	+20K sh	—	—	20,000
2015-02-10	Nexvet Biopharma plcC Conversion	VP Operations, General Counsel	CConversion	+1,696 sh	—	—	7,891
2015-02-10	Nexvet Biopharma plcSeries A Investment Preference SharesC Conversion	VP Operations, General Counsel	CConversion	−36 sh	—	—	0
2015-02-10	Nexvet Biopharma plcC Conversion	VP Operations, General Counsel	CConversion	+56 sh	—	—	132
2015-02-10	Nexvet Biopharma plcSeries B Preference SharesC Conversion	VP Operations, General Counsel	CConversion	−1,696 sh	—	—	0
2015-02-10	Nexvet Biopharma plcC Conversion	VP Operations, General Counsel	CConversion	+36 sh	—	—	76
2015-02-10	Nexvet Biopharma plcSeries B Preference SharesC Conversion	VP Operations, General Counsel	CConversion	−56 sh	—	—	0

Recent filings

Accepted (ET)
Aug 24
Farrell Geraldine T0001572426-17-000020
SEC(opens sec.gov)
Jul 54
Nexvet Biopharma plc0001171000-17-000051
SEC(opens sec.gov)
Sep 74
Nexvet Biopharma plc0001572426-16-000214
SEC(opens sec.gov)
Jul 14
Nexvet Biopharma plc0001572426-16-000189
SEC(opens sec.gov)
Mar 174
Nexvet Biopharma plc0001572426-16-000166
SEC(opens sec.gov)
Nov 244
Nexvet Biopharma plc0001171000-15-000112
SEC(opens sec.gov)

Companies

Nexvet Biopharma plcVP Operations, General Counsel

Address

C/O NEXVET BIOPHARMA PLC NIBRT; FOSTERS AVENUE, MOUNT MERRION

BLACKROCK, L2